Trial Profile
An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension [EXTENSION OF 700237724]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms PHIRST-2
- Sponsors Eli Lilly and Company
- 16 Jun 2014 New trial record
- 01 Mar 2012